Cells expressing mutant epidermal growth factor (EGF) receptors have been used to study mechanisms through which EGF increases phospholipase C (PLC) activity. C-terminal truncation mutant EGF (14, 41) that is dependent on the tyrosine kinase activity of the receptor (32). Phospholipase C--y (PLC--y), a member of the family of enzymes catalyzing hydrolysis of phosphatidylinositol bisphosphate to IP3 and 1,2-diacylglycerol (38), is phosphorylated on tyrosine residues by ligand-activated EGF and platelet-derived growth factor (PDGF) receptors in vivo and in vitro (26, 30, 35, 42 (1, 24, 25, 33) . The identified sites of tyrosine self-phosphorylation in the EGF receptor are located in the C terminus distal to the kinase domain at residues
The intrinsic protein tyrosine kinase activity of the epidermal growth factor (EGF) receptor is essential for the diverse biochemical responses of cells to the growth factor (8, 15) . Stimulation of the phosphatidylinositol pathway to generate the second messengers inositol 1,4,5-trisphosphate (1P3) and 1,2-diacylglycerol is a prominent early response to EGF (14, 41) that is dependent on the tyrosine kinase activity of the receptor (32) . Phospholipase C--y (PLC--y), a member of the family of enzymes catalyzing hydrolysis of phosphatidylinositol bisphosphate to IP3 and 1,2-diacylglycerol (38) , is phosphorylated on tyrosine residues by ligand-activated EGF and platelet-derived growth factor (PDGF) receptors in vivo and in vitro (26, 30, 35, 42) . The major identified sites of tyrosine phosphorylation are residues 771, 783, and 1254 with a minor site at 472 in PLC--y (19, 43) . Analysis of site-directed mutation of these residues indicates that Y783 and to a lesser extent Y1254 are essential to PDGF-stimulated inositol phospholipid hydrolysis in vivo (18) . In vitro studies indicate that phosphorylated PLC--y is more active when assayed under carefully defined conditions with Triton X-100 or profilin that may sequester the substrate (13, 34) . However, under standard conditions without profilin or Triton X-100, results of in vitro assays of the activity of normal and PLC enzymes mutated to contain phenylalanine replacements of tyrosine at residues 771, 783, and 1254 from control and PDGF-treated cells were similar (18) . Conditions that are necessary in vivo are incompletely defined, but these results suggest that factors additional to tyrosine phosphorylation may be necessary to couple ligand-activated growth factor receptors to PLC-y activation.
Analysis of mutant EGF receptors revealed that deletion * Corresponding author.
of 213 to 228 carboxyl-terminal amino acids abolished EGFstimulated increases in cytosolic calcium concentrations ([Ca2+] i) (7) . These C-truncated EGF receptors exhibited enhanced ligand-dependent protein tyrosine kinase activity in vivo (45) and enhanced mitogenic activity (46) . The failure to increase [Ca2+] i suggested deletion of sequences essential for coupling activated EGF receptors to the phosphatidylinositol pathway. This could result from failure to phosphorylate PLC--y or altered association of PLC--y with activated kinase-active EGF receptors. Studies by Mayer and coworkers (27) (28) (29) indicate that regions homologous to those present in p6Osrc (src homology regions, SH2 domains) interact with tyrosine-phosphorylated and surrounding residues. Such interactions appear to account for the association of PLC--y, which contains two SH2 domains (38) , with ligand-activated but not with control or kinase-inactive EGF and PDGF receptors (1, 24, 25, 33) . The identified sites of tyrosine self-phosphorylation in the EGF receptor are located in the C terminus distal to the kinase domain at residues 992, 1068, 1086, 1148, and 1173 (10, 16, 45 (8) . A truncation mutant (c'1000) was created by removing the coding sequence for the C-terminal 186 amino acids of the EGF receptor. The cDNA for c'1000 F-992 was prepared by site-directed mutagenesis according to the method of Kunkel (22) . All mutant sequences were confirmed by the dideoxy chain termination procedure. cDNAs were transfected into recipient mouse B82L cells, which lack endogenous EGF receptor mRNA and protein (7) . Permanent clonal transfectants were selected, and the EGF receptor gene was amplified by increasing concentrations of methotrexate from 400 nM to 5 ,uM. Two or more clonal lines were established for each mutant EGF receptor.
Measurement of inositol phosphate production. Cells were grown in 6-cm plates containing Dulbecco modified Eagle medium, 5% dialyzed newborn calf serum, and 5 puM methotrexate. At 24 h before the cells were collected, the medium was replaced with 2 ml of medium containing 5 ,uCi of [3H]myoinositol per ml. Cells were treated with 20 mM LiCl for 20 min followed by bovine serum albumin (BSA) as control, EGF (100 nM), vasopressin (10 ,uM), ATP (10 ,uM), or GTP (10 p.M) for the times indicated at 37°C. LiCl was used to increase the inositol phosphate signal by inhibiting inositol phosphate and inositol bisphosphate phosphatases (4). Vasopressin, ATP, or GTP was used to verify the ability of cells to increase inositol phosphate formation. Cells were then washed with phosphate-buffered saline (PBS), and the cells were collected with 10% trichloroacetic acid. The trichloroacetic acid supernatants were extracted with ether, neutralized to pH 7.5, and fractionated on Dowex columns (3). The columns were washed with H20 and 60 mM sodium formate before the inositol phosphates were eluted with 0.2 M ammonium formate-100 mM formic acid (inositol phosphate), 0.4 M ammonium formate-100 mM formic acid (inositol bisphosphate), and 1 M ammonium formate-100 mM formic acid (1P3 and inositol tetraphosphate). Inositol phosphate separations were confirmed by using tritiumlabeled inositol phosphate standards (New England Nuclear). Samples were counted by diluting them with Aquamix and adding the tubes to a Beckman scintillation counter. Each datum point in Fig. 1 and 2 7 .2], 150 mM NaCl, 2 mM EDTA) after 5 min of treatment with either BSA (1 ,ug/ml) or EGF (100 nM). The extracts were cleared with immobilized staphylococcus A before immunoprecipitation with PLC-y monoclonal antibodies (39) . The sample pellets were washed twice with radioimmunoprecipitation assay buffer, once with 0.5 M NaCl, and once with H20. The samples were solubilized with Laemmli sample buffer, run on SDS-7.5% polyacrylamide gel electrophoresis (PAGE) gels, and transferred onto Immobilon membranes. PLC--y protein levels were determined by incubating the blot with a mixture of PLC--y monoclonal antibodies and developed with goat anti-mouse antibody conjugated with alkaline phosphatase. Protein phosphotyrosine levels were determined on the same blot by incubation with '25I-labeled anti-phosphotyrosine monoclonal antibody PY20 (12) and autoradiography. Densitometry was performed on both the colorimetric immunostained PLC--y and the phosphotyrosine autoradiogram developed after various times under linear conditions of both color and radioactivity. Levels of PLC-y tyrosine phosphorylation were determined in relation to the amount of PLC-y present.
Two-dimensional tryptic phosphopeptide mapping. Solubilized wild-type and c'973 EGF receptors were incubated with 100 nM EGF at 25°C for 20 min. Purified PLC--y (2.6 ,ug) was then added with the kinase assay mixture (20 mM HEPES [N-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; pH 7.4], 100 ,uM Na3VO4, 2 mM MnCl2, 10 mM MgCl2, 10 puM ATP, 10 ,uCi [y-32P]ATP [2 x 105 cpm pmol-1]) in a final assay volume of 25 ,ul. The samples were incubated for 5 min at 25°C, the reaction was stopped by the addition of Laemmli sample buffer, and the proteins were separated on an SDS-7.5% PAGE gel. PLC--y, identified by autoradiography, was eluted from the gel with 0.3% ammonium bicarbonate-0.3% SDS-2.3 M 3-mercaptoethanol (5) . The protein was oxidized with performic acid and treated overnight with 1 mg of trypsin per ml. After trypsinization, the samples were washed and resuspended in 2.5% formic acid-7.5% acetic acid, pH 1.9. The samples were loaded on a cellulose thin-layer chromatography plate (Kodak) and electrophoresed in the first dimension at 1 kV for 30 min at pH 1.9 followed by thin-layer chromatography in the second dimension for 5 h in n-butanol-pyridine-acetic acid (38:25:7.5). Phosphoamino acid analysis confirmed that phosphotyrosine was the only phosphoamino acid present.
Coimmunoprecipitation. After EGF treatment, cells were washed with PBS and collected by the addition of solubilization buffer containing 1% Nonidet P-40, 20 mM Tris [pH 8.0], 137 mM NaCl, 10% glycerol, 2 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 100 ,uM sodium vanadate, and 10 puM ammonium molybdate. The extracts were cleared by incubation with Sepharose beads, and the supernatant was incubated with a monoclonal antibody directed against the extracellular portion of the EGF receptor (528 immunoglobulin G) (11) coupled to Sepharose beads. The 528 immunoglobulin G-Sepharose beads were washed three times with the solubilization buffer and once with 10 mM Tris, pH 7.4. Proteins were solubilized with Laemmli sample buffer, separated on SDS-7.5% PAGE gels, and transferred onto Immobilon membranes. Blots were stained either with a mixture of PLC-y monoclonal antibodies or with a rabbit polyclonal antibody directed against the amino-terminal 13 amino acids of the EGF receptor. Figure 1 shows that in cells expressing kinase-active wild-type EGF receptors, EGF increased inositol phosphate formation up to eightfold. EGF had no effect on inositol phosphate formation in cells expressing kinase-inactive M-721 EGF receptors, confirming that tyrosine kinase is essential for this biological effect (32) . EGF also strongly increased inositol phosphate formation in cells expressing c'1022 EGF receptors. In contrast, EGFstimulated inositol phosphate formation was significantly less in cells expressing c'991, c'973, and c'958 EGF receptors, showing a less than twofold increase in total inositol phosphate formation. Cells expressing kinase-inactive M-721 c'973 EGF receptors showed no inositol phosphate response to EGF, indicating that the rise in inositol phosphates in cells expressing c'973 EGF receptors, although markedly diminished, reflected the tyrosine kinase activity of this receptor (Fig. 1 ). All cells equally increased inositol phosphate formation in response to a mixture of fetal calf serum and 10 ,uM vasopressin or 10 ,uM ATP or 10 puM GTP, indicating that the ability to respond was equivalent in all B82 cell clones (data not shown).
A summary of the range of effects of EGF on total inositol phosphate formation in B82 cells expressing wild-type and mutant receptors is shown in Table 1 . Data are pooled from enhanced in vivo tyrosine kinase activity of this receptor (45) . EGF-dependent increases in tyrosine phosphorylation of PLC--y were also similar (three-to fivefold) in cells expressing c'958 and c'1000 F-992 EGF receptors in which PLC--y activity is not increased and in cells expressing c'1022 and c'1000 EGF receptors in which PLC--y activity is increased (data not shown). These results indicate that the defect in PLC--y activation is not due to diminished tyrosine phosphorylation by activated EGF receptors. Rather, tyrosine-phosphorylated PLC-y is less active in cells expressing EGF receptors which lack a site of tyrosine self-phosphorylation than in cells expressing EGF receptors which contain a site of tyrosine self-phosphorylation.
Comparison of tryptic phosphopeptide maps of PLC--y phosphorylated by wild-type and c'973 EGF receptors. Because specific sites of tyrosine phosphorylation of PLC--y appear essential to growth factor activation of the enzyme (18) , the sites of tyrosine phosphorylation of purified PLC-y catalyzed by wild-type and c'973 EGF receptors were compared. Two-dimensional tryptic phosphopeptide maps of PLC--y indicate that both wild-type and c'973 EGF receptors catalyze tyrosine phosphorylation at the same sites (Fig. 4) . Peptide a contains tyrosine 783, peptide b represents an incompletely digested peptide containing both tyrosine 771 and tyrosine 783, and peptide c contains tyrosine 1254 (18) . Mixing the two tryptic digestions prior to separation confirmed the identity of the sites of tyrosine phosphorylation (Fig. 4C) . Further confirmation was provided by comigration with electrophoresis at pH 7.2 rather than 1.9 in the first dimension (data not shown). These in vitro studies indicate that the wild-type and c'973 EGF receptors catalyze tyrosine phosphorylation of PLC--y on the same sites. Although insufficient material was available for comparison of in vivo phosphorylated sites, previous studies indicated strict con- cordance between in vivo and in vitro sites of tyrosine phosphorylation of PLC--y (18, 19, 42) .
Comparison of the association of PLC--y with activated wild-type and c'973 EGF receptors in vivo. Because tyrosine phosphorylation of PLC--y was equivalent in cells expressing wild-type and c'973 EGF receptors, we examined the interaction between PLC-y and ligand-activated EGF receptors.
Cells were treated with EGF, and EGF receptors were isolated by using a monoclonal antibody. Immunoisolated receptors were analyzed by SDS-PAGE, transfer to Immobilon, and immunostaining with both a monoclonal anti-PLC-y antibody and an anti-EGF receptor peptide antibody. As shown in Fig. 5 , PLC-y is associated with ligandactivated wild-type EGF receptors. The slower migration of wild-type EGF receptors from EGF-treated cells shown in panel B is due to receptor self-phosphorylation. In contrast, EGF did not enhance association of PLC-y with c'973 EGF receptors (panel A). The small amount of PLC--y detected from untreated wild-type and from c'973 EGF receptorexpressing cells is nonspecific because these low levels of association are also seen in immunoprecipitates from cells that express c'688 EGF receptors that contain only 40 amino acids of the cytoplasmic domain. Equivalent amounts of EGF receptor were loaded (Fig. SB) , indicating that PLC--y specifically associates with the self-phosphorylated C terminus of the EGF receptor. There is thus a direct correlation between in vivo activation of PLC-y and its association with the EGF receptor. DISCUSSION PLC--y is a well-defined in vivo substrate for ligandactivated EGF and PDGF receptors (26, 30, 35, 43) . The correlation between in vivo PLC--y activation and tyrosine phosphorylation of PLC-y suggested that this covalent modification resulted in enzyme activation. Mutation of tyrosinephosphorylated residues 783 and 1254 in PLC--y abolished the ability of ligand-activated PDGF receptors to stimulate activity of transfected mutant PLC--y in vivo, supporting an essential role for tyrosine phosphorylation in PLC--y activation (18) .
The present results indicate that a site of tyrosine phosphorylation in the EGF receptor is necessary for EGF to activate PLC--y activity in vivo. Removal of the five identified sites of tyrosine self-phosphorylation in the C terminus of the EGF receptor (c'991, c'973, and c'958 EGF receptors) markedly impaired the ability of EGF to stimulate inositol phosphate formation. The necessity for at least one site of tyrosine self-phosphorylation was demonstrated by mutating (45) effectively signal other responses to EGF such as morphological changes, gene induction, and cell proliferation (7, 46, 47 Mutation of the kinase insert region of the PDGF receptor to remove a site of tyrosine self-phosphorylation abolished PDGF-stimulated increases in phosphatidylinositol 3-kinase activity and association of this enzyme with the PDGF receptor (17) . The present study indicates that activation of PLC--y by EGF similarly requires a site of tyrosine selfphosphorylation in the EGF receptor. The SH2 domains of PLC--y bind tightly to sites of tyrosine phosphorylation in EGF and PDGF receptors (1, 25) . Similar to other proteins, tyrosine self-phosphorylation sites are proposed to create a high-affinity binding site for PLC--y via the -100-amino-acid SH2 domain (20, 25 (40) where it is tyrosine phosphorylated and placed in a conformation optimal for interaction with phosphatidylinositol bisphosphate substrate, which may be localized there or bound to profilin (13) . Studies which indicate that phosphatidylinositol 4-kinase and PI 4P 5-kinase are also tyrosine phosphorylated and associated with the EGF receptor (9) suggest that coupling of these two signal transduction pathways occurs in a local environment optimal for substrate production and conformational changes in PLC--y. These essential conformational changes in PLC-y appear to require both tyrosine phosphorylation and SH2-mediated interactions with activated EGF receptors. cipitation (1, 21, 26, 30) , this association correlates directly with in vivo activation of PLC-y. These results suggest that the association with self-phosphorylated EGF receptors is required for in vivo activation of PLC--y.
Although tyrosine phosphorylation of PLC--y appears essential for activation (18, 34) , the observation that c'973 EGF receptors catalyze tyrosine phosphorylation of PLC--y in vivo as effectively as wild-type EGF receptors but fail to activate the enzyme indicates that tyrosine phosphorylation of PLC--y is not sufficient for effective enzyme activation in vivo. Recent studies of a chimeric receptor composed of the EGF receptor-binding domain and the c-kit cytoplasmic domain also indicate a dissociation between tyrosine phosphorylation of PLC--y and in vivo enzyme activation (23) .
Taken together, these data indicate that both tyrosine phosphorylation of PLC--y and binding to the EGF receptor via SH2 domains of PLC--y to the EGF receptor sites of tyrosine phosphorylation are necessary for PLC-,y activation in vivo. Enzyme substrate interactions are not expected to require high-affinity interactions such as those dictated by SH2 regions, and c'973 EGF receptors efficiently catalyze tyrosine phosphorylation of PLC-y in vivo. Because there is evidence that tyrosine-phosphorylated PLC-y binds less tightly than does nonphosphorylated enzyme to self-phosphorylated EGF and PDGF receptors (21, 25) and because mutant nonphosphorylated PLC--y associates with self-phosphorylated PDGF receptors (18) , the present experiments suggest that although binding correlates directly with PLC--y activation, it may not be sufficient to explain in vivo activa-
